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Abstract: Ataxia telangiectasia (AT) is a rare genetic disorder characterized by immunodeﬁ  ciency, early onset neurological 
degeneration, hypersensitivity to ionizing radiation and a high incidence of lymphoid cancers. The disease results from 
bi-allelic mutations in the AT mutated (ATM) gene involved in cell cycle checkpoint control and repair of DNA double-strand 
breaks. Evidence has been accumulating that oxidative stress is associated with AT and may be involved in the pathogenesis 
of the disease. This led to a hypothesis that antioxidant therapy may mitigate the symptoms of AT, especially neurological 
degeneration and tumorigenesis. Consequently, several studies examined the effect of antioxidants in Atm deﬁ  cient mice 
used as an animal model of AT. N-acetyl-L-cysteine (NAC), EUK-189, tempol and 5-carboxy-1,1,3,3-tetramethylisoindolin-
2-yloxyl (CTMIO) have been tested for their chemopreventive properties and had some beneﬁ  cial effects. In addition to 
antioxidants, cancer therapeutic agent dexamethasone was examined for cancer prevention in Atm deﬁ  cient mice. Of the 
tested antioxidants, only NAC has wide clinical applications due to safety and efﬁ  cacy and is available as an over-the-counter 
dietary supplement. In this article, we review chemoprevention studies in Atm deﬁ  cient mice and, in more detail, our ﬁ  ndings 
on the effect of NAC. The short-tem study showed that NAC suppressed genome rearrangements linked to cancer. The 
long-term study demonstrated that NAC reduced both the incidence and multiplicity of lymphoma.
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Introduction
Ataxia Telangiectasia (AT) is an autosomal recessive human disorder caused by mutational inactivation 
of the AT mutated (ATM) gene. It is a severe pleiotropic disease characterized by early onset progressive 
neurological degeneration, high incidence of cancer, immunodeﬁ  ciency, oculocutaneous telangiectasias, 
growth retardation, endocrine abnormalities, infertility, and hypersensitivity to ionizing radiation (Boder, 
1985; Boder et al. 1970; Gatti, 2001; Lavin et al. 1997; Meyn, 1999). The most prominent neuropathological 
manifestation of AT is atrophy of the cerebellar cortex associated with the loss of Purkinje and granule 
cells. An early sign of neurological degeneration is ataxia characterized by unstable gait and lack of 
coordination of head and eyes. About 40% of AT patients develop cancer, mostly in the lymphoid organs 
early in life and solid tumors at later age (Taylor et al. 1996; Xu, 1999). AT patients display a variety of 
lymphoid tumors including non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and several types 
of leukemia, most tumors being of T cell origin. AT patients suffer from increased mortality due to 
malignancy, infections of the respiratory system and various rare complications (Boder, 1975; Crawford 
et al. 2006). It is possible to alleviate some of the clinical symptoms of AT. For example, sinopulmonary 
infections respond well to antibiotics or modest improvements in neurological symptoms can sometimes 
be achieved by L-DOPA derivatives, dopamine agonists or steroids (Lavin et al. 2007). However, currently 
there is no therapy available to prevent cancer or progressive neurodegeneration. The median survival 
of AT patients is calculated to be 19–25 years (Crawford et al. 2006).
The gene defective in AT, ATM, encodes a phosphatidylinositol-3’ related kinase that is involved in cell 
cycle checkpoint and repair responses to DNA double-strand breaks (DSBs) via a series of phosphorylated 
intermediary proteins including p53, Chk2, Brca1 and Nbs1 (Lavin et al. 2005; Savitsky et al. 1995; Shiloh, 
2003). A lack of ATM function results in genomic instability characterized by chromosome breaks, 
chromosome gaps, translocations and aneuploidy (Cohen et al. 1975; Gropp et al. 1967; Stumm et al. 2001). 
ATM deﬁ  ciency is also associated with elevated oxidative stress. ATM deﬁ  cient cells in culture are more 432
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sensitive to oxidative stress than normal cells, cells 
isolated from AT patients display elevated oxidative 
damage to lipids and DNA and AT patients have 
reduced plasma antioxidant concentrations (Reichen-
bach et al. 2002; Reichenbach et al. 1999; Yi et al. 
1990). Further evidence that AT is linked to oxidative 
stress stems from studies with Atm deﬁ  cient mice. 
Atm deﬁ  cient mice exhibit elevated levels of reactive 
oxygen species (ROS), oxidative damage to proteins 
and DNA, lipid peroxidation and alterations in the 
levels and function of antioxidative enzymes (Barlow 
et al. 1999; Ito et al. 2007; Kamsler et al. 2001; Quick 
et al. 2001; Reliene et al. 2004b). Atm deﬁ  cient mice 
largely recapitulate the human disease (Barlow et al. 
1996; Borghesani et al. 2000; Elson et al. 1996; Xu 
et al. 1996). Similar to human AT phenotype, Atm 
deﬁ  cient mice display growth retardation, infertility, 
immunodeﬁ  ciency, radiosensitivity and malignant 
lymphomas (Barlow et al. 1996; Elson et al. 1996; 
Xu et al. 1996). Although Atm deﬁ  cient mice do not 
show the gross cerebellar degeneration that charac-
terizes the human disease, more subtle alterations in 
the cerebellum have been observed and are consistent 
with a mild decrease in their motor performance 
(Barlow et al. 1996; Borghesani et al. 2000; Kuljis 
et al. 1997).
Since oxidative stress has been evidenced in AT 
and oxidative stress is linked to neurodegenerative 
diseases and cancer, it has been suggested that it 
may contribute to neuropathological and malignant 
phenotype of AT, while antioxidants might allevi-
ate these symptoms (Barzilai et al. 2002). This 
hypothesis has been tested in Atm deﬁ  cient mice 
in several studies that examined the effect of anti-
oxidants EUK-189, tempol, CTMIO and NAC 
(Browne et al. 2004; Gueven et al. 2006; Ito et al. 
2007; Reliene et al. 2006; Schubert et al. 2004). In 
addition to antioxidants, dexamethasone (Dx), 
which is used in chemotherapy of hematological 
malignancies, was studied for cancer chemopre-
vention in Atm deﬁ  cient mice (Yan et al. 2002).
Chemopreventive Agents
NAC
NAC is a low molecular weight thiol-containing 
molecule that is readily taken up by the cells (Kelly, 
1998). It directly inhibits reactive electrophiles and 
ROS and can enhance the synthesis of glutathione 
(GSH) as a precursor of cysteine (De Flora et al. 
2001). NAC has been used in the clinical practice 
more than 40 years and has found wide applications 
(Decramer et al. 2005; Kelly, 1998; Van Schooten 
et al. 2002). NAC has been used for the treatment 
of respiratory diseases as a mucolytic agent (Webb, 
1962), for acetaminophen overdose, where it res-
cues from GSH depletion in the liver (Prescott et al. 
1977), and is available as an over-the-counter 
dietary supplement. NAC is most frequently taken 
orally and thus, we examined the effect of NAC 
on Atm deﬁ  cient mice by the oral route (Reliene 
et al. 2004b; Reliene et al. 2006). We gave NAC 
supplemented drinking water to Atm deﬁ  cient mice 
from fertilization throughout their life. In this treat-
ment scenario, Atm 
+/− mice were crossed with each 
other and dams were given NAC-containing drink-
ing water throughout pregnancy and lactation. 
After weaning (at about 3 weeks of age) animals 
continued to receive NAC in their drinking water. 
The major reason to start antioxidant administra-
tion as early as from fertilization was to protect 
against genome rearrangements that can occur 
during mouse development and lead to carcino-
genesis later in life.
Effect of NAC on cancer prevention
We found that NAC intake signiﬁ  cantly increased 
the lifespan and reduced both the incidence and 
multiplicity of lymphoma in Atm deﬁ  cient mice 
(Reliene et al. 2006). The mean survival of NAC 
treated mice was 68 weeks, while that of untreated 
mice was only 50 weeks (p = 0.03). We completed 
gross necropsy and histopathological examination 
to determine a possible cause of death. Consistent 
with previous studies, the most frequent tumor in 
Atm deﬁ  cient mice was lymphoma (Barlow et al. 
1996; Elson et al. 1996; Xu et al. 1996). Remark-
ably, the incidence of lymphoma in NAC treated 
mice decreased by two-fold (37.5 versus 76.5%, 
p = 0.02). We examined the lymphoma tissue dis-
tribution and found tumors in various organs in 
both NAC treated and control mice (Fig. 1). How-
ever, in NAC treated Atm deﬁ  cient mice, the mul-
tiplicity of tumors decreased from 4.6 to 2.8 tumors 
per mouse (p = 0.038). Lymphoma burden was 
similar in the thymus, spleen and liver, while in 
other organs, such as lymph nodes, lung, heart, 
kidney, pancreas, stomach, duodenum and adrenal 
glands there were fewer or no tumors in the NAC 
treatment group (Fig. 1).
Subsequently the ﬁ  nding that NAC extends the 
reduced lifespan of Atm deficient mice was 433
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reproduced by another group of researchers (Ito 
et al. 2007). NAC was administered in drinking 
water and treatment was started from birth. In this 
study, the mean survival was approximately 20 
weeks and 43 weeks in untreated Atm deﬁ  cient 
mice and NAC treatment group, respectively.
Possible Mechanism of Lymphoma 
Prevention by NAC
Several studies examined the molecular action 
mechanism of NAC in cancer prevention in Atm 
deﬁ  cient mice. NAC reduced abnormally high 
DNA synthesis and ROS levels in lymphocytes 
from Atm deﬁ  cient mice (Ito et al. 2007; Yan et al. 
2001). ROS causes oxidative DNA damage, while 
upregulated DNA synthesis results in a lack of 
time required for repair of damaged DNA template 
before it is used for replication. Oxidative DNA 
damage is often translated into irreversible 
genome rearrangements during replication 
(Kuzminov, 2001). We found that NAC sup-
pressed both oxidative DNA damage and DNA 
deletions in Atm deﬁ  cient mice supporting the 
interpretation that DNA deletions may be a con-
sequence of abnormal DNA synthesis and oxida-
tive damage (Fig. 2) (Reliene et al. 2004b). These 
studies showed that NAC may reduce cancer 
incidence by reducing oxidative stress and 
genomic instability.
Other studies demonstrated that NAC reduces 
the number of aberrant V(D)J rearrangements 
between T cell receptor (TCR) β and γ genes, which 
can cause lymphoma (Ito et al. 2007; Lista et al. 
1997). In fact, tumors in Atm deﬁ  cient mice exhibit 
abnormal TCR rearrangements suggesting that 
development of lymphoma may be driven by 
aberrant V(D)J recombination (Liyanage et al. 
2000). NAC reduced the number of defective 
rearrangements and restored the decreased T cell 
numbers, which probably accounted for reduced 
lymphomagenesis (Ito et al. 2007).
ROS have also been proposed to be involved in 
tumor metastasis, a process that includes epithelial-
mesenchymal transition, migration, invasion of the 
tumor cells and angiogenesis (Nishikawa et al. 
2006; Wu, 2006). ROS can oxidize the critical 
target molecules and thereby play a role in the 
transcription and expression of genes implicated 
in tumor progression. NAC can counteract some 
effects of ROS in tumor progression. NAC has 
been reported to limit invasion of human bladder 
cancer cells by inhibiting both the production and 
activity of matrix metalloproteinase-9 involved in 
cancer invasion and metastasis (Kawakami et al. 
2001). NAC inhibits vascular endothelial growth 
factor (VEGF) production and growth of 
angiogenesis-driven Kaposi’s sarcoma in nude 
mice (Albini et al. 2001), promotes anti-angiogenic 
factor angiostatin production and results in 
endothelial apoptosis and vascular collapse in an 
Figure 1. Lymphoma tissue distribution in untreated and NAC 
treated Atm deﬁ  cient mice. Only mice that had lymphoma are included 
in the calculation. Black bars depict untreated mice, gray bars show 
NAC treated mice. Lymph nodes affected were mesenteric and/or 
peripheral, thoratic and perirenal. Lymphoma in the heart was seen in 
epicardium and/or pericardium. Taken from (Reliene et al. 2007).
Figure 2. The correlation between oxidative DNA damage and 
the frequency of DNA deletions. Oxidative DNA damage was 
determined as the number of oxidized guanine residues per 10
6 
guanine residues (8-OHdG/10
6dG) using HPLC. The frequency of 
DNA deletions was determined as the number of eye-spots in the 
retinal pigment epithelium (RPE) of the eye. The eye-spots are derived 
from 70 kb DNA deletions at the pink-eyed unstable (p
un) locus of the 
pink-eyed dilution (p) gene, which result in black pigment accumula-
tion in the affected cells (Reliene et al. 2004a). Data for untreated 
mice are shown by a black triangle; results for NAC treated mice are 
shown by a gray rectangle. Taken from (Reliene et al. 2007).434
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experimental breast cancer assay (Agarwal et al. 
2004). We found that NAC reduced the multiplicity 
of lymphoma in Atm deﬁ  cient mice, which may be 
explained by NAC’s anti-invasive and anti- 
angiogenic properties (Reliene et al. 2006). The 
effect was most pronounced in nonlymphoid 
organs supporting the observation of other studies 
that NAC exhibits an anti-metastatic effect.
The studies reviewed in this article show that 
NAC signiﬁ  cantly reduces lymphomagenesis in 
Atm deﬁ  cient mice but these positive effects by no 
means suggest that NAC administration can 
replace the missing Atm protein. It has been 
recently reported that ATM prevents cancer pro-
gression through detection and response to 
oncogene-induced DNA replication stress and 
DNA damage (Bartkova et al. 2005). In this report, 
NAC had only a marginal effect suggesting that 
DNA damage caused by hyperproliferative onco-
genic stimuli cannot be suppressed by antioxidants. 
Similarly in our studies the cancer frequency and 
multiplicity were signiﬁ  cantly reduced but still 
much elevated above wildtype levels.
EUK-189
EUK-189, a salen-manganese compound with 
catalase and superoxide dismutase activities, has 
been previously shown to be neuroprotective in 
animal models characterized by oxidative damage 
(Doctrow et al. 2002; Melov et al. 2001). Atm deﬁ  -
cient mice were treated with EUK-189 from 40 
days of age via an osmotic pump implanted sub-
cutaneously. The EUK-189 treatment improved 
performance on a rotarod and showed a trend 
towards prolonged life span (p = 0.08) (Browne 
et al. 2004). When the study was terminated at 
5 months, 31% vehicle-treated and 56% EUK-
189-treated animals were still alive (Browne 
et al. 2004).
Tempol
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-
N-oxyl) is a stable nitroxide free radical and 
superoxide dismutase mimetic (Damiani et al. 
2000; Hahn et al. 1994; Mitchell et al. 1990). 
Tempol detoxiﬁ  es oxygen metabolites, oxidizes 
redox-active trace metal ions, reduces quinone 
radicals and, in biological systems, is itself reduced 
by GSH and ascorbic acid (Branca et al. 1988; 
Krishna et al. 1992; Krishna et al. 1996; May 
et al. 2005). Tempol mixed in a mouse chow was 
chronically administered to Atm deﬁ  cient mice 
either from fertilization or from weaning (Schubert 
et al. 2004). Tempol had no effect, when the treat-
ment was started from fertilization. The intake of 
tempol food signiﬁ  cantly increased the life span 
(mean survival 62 versus 30 weeks) in the second 
treatment scenario. Tempol reduced ROS levels, 
protein oxidation and restored mitochondrial mem-
brane potential in thymocytes implying that che-
moprevention by tempol is associated with its 
antioxidant activity. However, tempol treatment 
also reduced cell number in the thymus and 
decreased weight gain in Atm deﬁ  cient mice. These 
effects were explained by tempol anti-proliferative 
activity and unknown effects, respectively. A pos-
sibility of caloric restriction was ruled out, mainly 
because no decrease in the intake of food contain-
ing tempol was observed.
CTMIO
Like tempol, CTMIO belongs to a class of stable 
nitroxide free radicals (Damiani et al. 2000; Hahn 
et al. 1994; Mitchell et al. 1990). The effect of 
CTMIO intake through drinking water was 
recently examined in Atm deﬁ  cient mice (Gueven 
et al. 2006). The treatment was started immedi-
ately after weaning. CTMIO prolonged the sur-
vival of Atm deficient mice resulting in the 
median survival of 54 weeks versus 16 weeks. 
CTMIO chemoprevention mechanism does not 
appear to involve apoptosis, as tumors from 
CTMIO treated mice did not show higher levels 
of apoptosis compared to tumors from untreated 
Atm deﬁ  cient mice. However, it was not shown 
whether CTMIO induced apoptosis in mice with-
out tumors.
Dx
Dx is a synthetic glucocorticoid hormone used in 
the chemotherapy of hematological malignancies 
(Goss, 1992; Keating et al. 1997) for its anti-
inﬂ  ammatory and cytotoxic effects (Greenstein 
et al. 2002). In a chemoprevention study with Dx, 
the untreated Atm
−/− mice died at 2.2–4.8 month of 
age, while 50% of Dx treated Atm
−/− mice survived 
up to 6 months when treatment was started at 4 
weeks of age, and all Atm
−/− mice survived for 
10 months when the treatment began at 2 weeks 
of age, implying that Dx is more effective when 
given during earlier postnatal stages than later (Yan 
et al. 2002).435
Chemoprevention in Atm
−/− mice
Clinical Medicine: Oncology 2008:2 
Conclusion
The effect of NAC, EUK-189, tempol, and CTMIO 
was studied in Atm deﬁ  cient mice to understand 
whether antioxidant therapy has a potential in the 
management of AT. All the described compounds 
had some beneﬁ  cial effects, particularly, in extend-
ing the life span and reducing lymphomagenesis. 
Of the tested antioxidants, only NAC has a long 
history of safety and efﬁ  cacy in the clinical set-
tings. Therefore, NAC has a strong potential to 
emerge as a dietary supplement against high risk 
of cancer in AT and possibly other oxidative stress 
linked disorders. At present there is an ongoing 
clinical trial in pediatric AT patients, where a 
cocktail of antioxidants including NAC, is 
employed (personal communication with Dr. G. 
Berry, Thomas Jefferson University Medical 
College, also see http://www.treat-at.org). The trial 
is being conduced in Philadelphia, PA, and is a 
result of the combined efforts of the national 
organization to Treat-AT, Dr. Gerald Berry and his 
colleagues at DuPont Children’s and Children’s 
Hospital of Philadelphia, and SHS International 
Ltd (Liverpool, UK). The aim of this study is to 
determine whether lymphocytes from AT patients 
show abnormal levels of ROS and increased apop-
tosis and whether chronic broad antioxidant 
therapy retards development of lymphocyte and 
cerebellar dysfunction or arrest destruction of 
these tissues.
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